The first set of guidelines has been published for clinicians who wish to prescribe the new drug aducanumab (Aduhelm) and to properly monitor its administration. The recommendations fill the gaps between the FDA’s prescribing information and real-world clinical use, the authors say.
A bout with COVID-19 can cause dementia-like brain changes and related functional decline, especially for seniors and in people who lose their sense of smell, researchers are finding.
There are more younger people living with dementia in the world than previously thought, and that number is probably an underestimate. That is a conclusion of a systematic review of 95 studies that included millions of patients.
Providers will end 2021 better than they started: report … Early-onset dementia prevalence higher than previously estimated, with Alzheimer’s diagnoses leading the surge … Rare COVID-19 vaccine breakthroughs hit seniors disproportionately … Federal oversight, healthcare fraud prosecutions netted $3.1 billion last fiscal year
The order calls for HHS rules that would allow over-the-counter sales of hearing aids. Most people must visit a specialist or doctor for access to the devices — a needless and costly barrier, according to the White House.
The FDA’s new label restricts Aduhelm’s use to Alzheimer’s patients with mild cognitive impairment or mild dementia, drugmaker Biogen announced Thursday.
Wide variation seen in continuity of nursing staff for home health care visits to dementia patients following hospitalization
‘Gold standard’ for dementia care focuses on person-centered practices: panel … Delta, now a ‘variant of concern,’ accounts for 10% of new U.S. COVID cases, CDC says … Vaccine effort turns into slog as infectious variant spreads … AMA adopts policies to tackle prior authorization burdens
Chatbots for dementia still in their infancy, tech researchers find … What to know about new Alzheimer’s drug Aduhelm, from scientist who led the trials … Advocacy group urges OIG to investigate FDA’s approval of new Alzheimer’s drug … First patient receives controversial Biogen Alzheimer’s drug at hospital … LTC care needs will double by 2065 … FDA approves Novartis’ drug for aggressive prostate cancer following positive trial results
Cultural practices and disease processes may explain why Latino adults with dementia experience faster functional decline and higher rates of depression and anxiety, investigators say.
